AzTrials
AzTrials

Blood Transfusion; HemoglobinemiaNCT03138200

The Role of Central Venous Oxygen Saturation (ScvO2) as an Indicator of Blood Transfusion in the Critically Ill

A study testing Blood transfusion in people with Blood Transfusion; Hemoglobinemia and Hypoxia, run by Szeged University at 2 sites in Hungary.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Transfusion of red blood cells is an everyday practice in critical care with the primary aim of restoring adequate tissue oxygenation. However, blood transfusion may also be harmful and costly, therefore a so called restrictive transfusion regime has been suggested by recent guidelines. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Blood Transfusion; Hemoglobinemia, Hypoxia, Anemia
What is being tested?
Blood transfusion
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
160 participants
Where
2 sitesHungary
Study dates
8 Mar 2017to 1 Mar 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult (>18 y)
  • Critically ill anemic but hemodynamically stable patients treated on the ICU in whom transfusion is considered by the attending physician
  • Routine ICU monitoring: invasive blood pressure, CVC, hourly urine output
  • Anemia is defined as Hb<100 g/L
  • Hemodynamic stability is defined as:
  • heart rate (HR)<100/min,
Show all 11Show fewer
  • mean arterial pressure (MAP)>60 mmHg
  • no or "minimal" requirement of noradrenaline (NA): compensation for sedation not exceeding 5 µg/min
  • stable homeostasis:
  • pH: 7.30-7.45 ii. HCO3 > 20 mmol/L iii. lactate < 2 mmol/L e. normal hourly urine output for the last 2 hours not facilitated by diuretics: >0.5ml/kg/h
  • Central venous catheter in situ (position in the v. cava superior confirmed by chest x-ray)

Who cannot join

  • Pregnancy
  • Head injury requiring ICP monitoring guided control of ICP
  • Shock of any origin
  • Patients with heart failure
  • Patients with renal failure

Trial locations and contacts

2 sites in 1 country.

Hungary2 sites, 1 recruiting
  • Department of Anaesthesia and Intensive Care, Medical Centre, Hungarian Defence Force

    Budapest, 1134

    Active, not recruiting
  • Department of Anaesthesiology and Intensive Therapy

    Szeged, Csongrád megye, 6725

    Petra Dalmann, +36 62 - 545 168, office.aiti@med.u-szeged.hu

    Recruiting

Other trials in Hungary

About this study

Transfusion of red blood cells is an everyday practice in critical care with the primary aim of restoring adequate tissue oxygenation. However, blood transfusion may also be harmful and costly, therefore a so called restrictive transfusion regime has been suggested by recent guidelines. These transfusion guidelines consider certain levels of hemoglobin as transfusion trigger, which on its own gives little information if any about the balance between oxygen delivery (DO2) and consumption (VO2). Hence, there is a clear need for additional physiologic transfusion trigger values. One of the potentially useful and easily obtainable physiological parameters is the central venous oxygen saturation (ScvO2), which has been shown to be a potential transfusion trigger value in hemodynamically stable but anemic patients. However, the role of ScvO2 as a transfusion trigger value was examined only in a retrospective observational study and in animal experiment.

The normal value of ScvO2 in a resting adult at rest is around 70-75%, which is the product of the VO2 and DO2 relationship. Low ScvO2 usually indicates inadequate DO2. It was found in an observational study that if ScvO2>70% before transfusion due to transfusion only the value of hemoglobin increased but the value of ScvO2 did not change. This finding indicates that the DO2 may have been adequate in spite of the low hemoglobin value and the transfusion may have been unnecessary. In one of their recent animal experiments, the investigators reported that in an isovolemic-anemia model the value of ScvO2<70% was only reached when the value of hemoglobin was far less, 59 g/L, than the recommended lowest value of 70g/L as transfusion trigger by guidelines.

Read more

Despite the pathophysiological rationale and the encouraging results of retrospective studies and animal experiments, prospective randomized trials in order to test the effects of an ScvO2-assisted transfusion protocol are yet to be performed.

The aim of this study is to investigate the effects of an ScvO2-assisted transfusion protocol as compared to the guideline-based, hemoglobin levels guided transfusion practice.

Being tested
Blood transfusion
Keywords
Transfusion, ScvO2, Hemoglobin
Medical subject headings
Hypoxia, Anemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Blood transfusionBiological

    Blood transfusion is a safe, routine procedure in which blood is given to a patient through an intravenous cannula inserted into one of the patient's veins.

Study groups in NCT03138200
Study groupRoleWhat they receive
Blood transfusion based on central venous oxygen saturationOtherNot described
Receives: Biological: Blood transfusion

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison of number of transfuion events in the two groups

    Comparison of how many tranfusions were performed based on ScvO2 to conventional, hemoglobin based transfusion.

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 May 2017
  2. Study start8 Mar 2017
  3. Primary completion1 Mar 2019 (estimated)
  4. Study completion1 Mar 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
160 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03138200
Sponsor's protocol ID
ScvO2 transfusion
Status last verified
Apr 2017
First submitted
8 Mar 2017
Last updated
3 May 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Blood Observational Study Investigators of ANZICS-Clinical Trials Group; Westbrook A, Pettila V, Nichol A, Bailey MJ, Syres G, Murray L, Bellomo R, Wood E, Phillips LE, Street A, French C, Orford N, Santamaria J, Cooper DJ. Transfusion practice and guidelines in Australian and New Zealand intensive care units. Intensive Care Med. 2010 Jul;36(7):1138-46. doi: 10.1007/s00134-010-1867-8. Epub 2010 May 4.

    PubMed 20440603
  • Vallet B, Robin E, Lebuffe G. Venous oxygen saturation as a physiologic transfusion trigger. Crit Care. 2010;14(2):213. doi: 10.1186/cc8854. Epub 2010 Mar 9.

    PubMed 20236457
  • Adamczyk S, Robin E, Barreau O, Fleyfel M, Tavernier B, Lebuffe G, Vallet B. [Contribution of central venous oxygen saturation in postoperative blood transfusion decision]. Ann Fr Anesth Reanim. 2009 Jun;28(6):522-30. doi: 10.1016/j.annfar.2009.03.013. Epub 2009 May 20. French.

    PubMed 19467825
  • Kocsi S, Demeter G, Fogas J, Erces D, Kaszaki J, Molnar Z. Central venous oxygen saturation is a good indicator of altered oxygen balance in isovolemic anemia. Acta Anaesthesiol Scand. 2012 Mar;56(3):291-7. doi: 10.1111/j.1399-6576.2011.02622.x. Epub 2012 Jan 19.

    PubMed 22260228

Questions about this trial

What is this clinical trial studying?

A study testing Blood transfusion in people with Blood Transfusion; Hemoglobinemia and Hypoxia, run by Szeged University at 2 sites in Hungary.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 May 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Hungary. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparison of number of transfuion events in the two groups (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03138200, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in